Mereo BioPharma (MREO) Other Accumulated Expenses (2022 - 2026)

Mereo BioPharma (MREO) has 5 years of Other Accumulated Expenses data on file, last reported at $905000.0 in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $905000.0, up 1.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $905000.0 (up 1.23% YoY), and the FY2025 annual result was $741000.0, down 32.33% from the prior year.
• Other Accumulated Expenses improved to $905000.0 in Q1 2026 per MREO's latest filing, from $741000.0 in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $3.4 million in Q2 2024 and troughed at $622000.0 in Q3 2025.
• A 5-year average of $1.3 million and a median of $905000.0 in 2026 frame the typical range for Other Accumulated Expenses.
• On a YoY basis, Other Accumulated Expenses climbed as much as 24.51% in 2025 and fell as far as 77.38% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $1.1 million in 2022, then retreated by 4.67% to $1.0 million in 2023, then rose by 7.25% to $1.1 million in 2024, then tumbled by 32.33% to $741000.0 in 2025, then advanced by 22.13% to $905000.0 in 2026.
• Business Quant data shows MREO's Other Accumulated Expenses at $905000.0 in Q1 2026, $741000.0 in Q4 2025, and $622000.0 in Q3 2025.